• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

造血系统的结构可以解释慢性髓性白血病的进展。

The structure of the hematopoietic system can explain chronic myeloid leukemia progression.

机构信息

Department of Biological Physics, Eötvös Loránd University, Budapest , Hungary.

Department of Biological Physics, ELTE-MTA 'Lendület' Biophysics Research Group, Budapest , Hungary.

出版信息

Sci Rep. 2023 Apr 3;13(1):5411. doi: 10.1038/s41598-023-32400-2.

DOI:10.1038/s41598-023-32400-2
PMID:37012292
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10070397/
Abstract

Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature blood cells. Here we introduce a general model of hierarchical cell division explaining the particular progression of CML as resulting from the structure of the hematopoietic system. Driver mutations confer a growth advantage to the cells carrying them, for instance, the BCR::ABL1 gene, which also acts as a marker for CML. We investigated the relation of the BCR::ABL1 mutation strength to the hematopoietic stem cell division rate by employing computer simulations and fitting the model parameters to the reported median duration for the chronic and accelerated phases. Our results demonstrate that driver mutations (additional to the BCR::ABL1 mutation) are necessary to explain CML progression if stem cells divide sufficiently slowly. We observed that the number of mutations accumulated by cells at the more differentiated levels of the hierarchy is not affected by driver mutations present in the stem cells. Our results shed light on somatic evolution in a hierarchical tissue and show that the clinical hallmarks of CML progression result from the structural characteristics of blood production.

摘要

几乎所有癌症类型都具有癌症的特征和相似的肿瘤形成方式

由体细胞的随机突变驱动。在慢性髓细胞白血病(CML)中,这个进化过程可以从无症状的持久慢性期追踪到最终快速演变的爆发期。CML 中的体细胞进化发生在健康血液生成的背景下,这是一个细胞分裂的层次过程;由自我更新并分化为成熟血细胞的干细胞启动。在这里,我们引入了一个层次细胞分裂的一般模型,解释了 CML 的特定进展是如何源自造血系统的结构。驱动突变赋予携带它们的细胞生长优势,例如,BCR::ABL1 基因,它也是 CML 的标志物。我们通过计算机模拟研究了 BCR::ABL1 突变强度与造血干细胞分裂率之间的关系,并将模型参数拟合到报告的慢性期和加速期的中位数持续时间。我们的结果表明,如果干细胞分裂足够慢,驱动突变(除了 BCR::ABL1 突变之外)是解释 CML 进展所必需的。我们观察到,在层次结构中更分化水平的细胞积累的突变数量不受干细胞中存在的驱动突变的影响。我们的结果揭示了层次组织中的体细胞进化,并表明 CML 进展的临床特征源自血液生成的结构特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/436d278da3ee/41598_2023_32400_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/a4d135579969/41598_2023_32400_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/3d16f83a0a0b/41598_2023_32400_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/de5549fc7b5c/41598_2023_32400_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/9857751986d6/41598_2023_32400_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/cba70af1e5eb/41598_2023_32400_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/436d278da3ee/41598_2023_32400_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/a4d135579969/41598_2023_32400_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/3d16f83a0a0b/41598_2023_32400_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/de5549fc7b5c/41598_2023_32400_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/9857751986d6/41598_2023_32400_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/cba70af1e5eb/41598_2023_32400_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5c5/10070397/436d278da3ee/41598_2023_32400_Fig6_HTML.jpg

相似文献

1
The structure of the hematopoietic system can explain chronic myeloid leukemia progression.造血系统的结构可以解释慢性髓性白血病的进展。
Sci Rep. 2023 Apr 3;13(1):5411. doi: 10.1038/s41598-023-32400-2.
2
miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.miR-96 通过靶向慢性髓系白血病原始细胞转化中的 BCR-ABL1 癌基因发挥肿瘤抑制作用。
Biomed Pharmacother. 2019 Nov;119:109413. doi: 10.1016/j.biopha.2019.109413. Epub 2019 Sep 10.
3
The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.费城染色体阳性慢性髓性白血病患者行异基因造血细胞移植后 BCR-ABL1 突变的临床意义。
Transplant Cell Ther. 2022 Jun;28(6):321.e1-321.e8. doi: 10.1016/j.jtct.2022.03.009. Epub 2022 Mar 13.
4
Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.p53的获得性缺失诱导表达p210(bcr/abl)的造血细胞发生原始细胞转化:一项关于人类慢性粒细胞白血病急变期的转基因研究。
Blood. 2000 Feb 15;95(4):1144-50.
5
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.一种由BCR/ABL与NUP98/HOXA9协同作用诱导的慢性粒细胞白血病急变期小鼠模型。
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7622-7. doi: 10.1073/pnas.102583199.
6
Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.Fyn 的表达和活性介导慢性髓性白血病的增殖和原始细胞特征。
PLoS One. 2012;7(12):e51611. doi: 10.1371/journal.pone.0051611. Epub 2012 Dec 17.
7
Chronic myeloid leukemia stem cells.慢性髓性白血病干细胞
Hematology Am Soc Hematol Educ Program. 2008:436-42. doi: 10.1182/asheducation-2008.1.436.
8
A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.慢性髓性白血病疾病进展机制的因果贝叶斯网络模型
J Theor Biol. 2017 Nov 21;433:94-105. doi: 10.1016/j.jtbi.2017.08.023. Epub 2017 Sep 1.
9
Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.在晚期慢性期和加速期对伊马替尼敏感的慢性粒细胞白血病(CML)患者中存在新型复合BCR-ABL突变,表明这些突变在CML进展中可能发挥的作用。
Cancer Biol Ther. 2017 Apr 3;18(4):214-221. doi: 10.1080/15384047.2017.1294289. Epub 2017 Feb 21.
10
Chronic myelogenous leukemia: molecular and cellular aspects.慢性粒细胞白血病:分子与细胞层面
J Cancer Res Clin Oncol. 1998;124(12):643-60. doi: 10.1007/s004320050228.

引用本文的文献

1
Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis.酪氨酸激酶抑制剂治疗慢性髓性白血病的血液学不良事件:一项系统评价与荟萃分析
Cancers (Basel). 2023 Aug 31;15(17):4354. doi: 10.3390/cancers15174354.

本文引用的文献

1
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版:髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
2
Clonal dynamics of haematopoiesis across the human lifespan.人类生命全程中的造血克隆动力学。
Nature. 2022 Jun;606(7913):343-350. doi: 10.1038/s41586-022-04786-y. Epub 2022 Jun 1.
3
Trade-off between reducing mutational accumulation and increasing commitment to differentiation determines tissue organization.
在减少突变积累和增加分化承诺之间进行权衡,决定了组织的结构。
Nat Commun. 2022 Mar 29;13(1):1666. doi: 10.1038/s41467-022-29004-1.
4
Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML.基于模型的推断和分类:TKI 停药和剂量减少对 CML 患者免疫控制机制的影响。
Cancer Res. 2020 Jun 1;80(11):2394-2406. doi: 10.1158/0008-5472.CAN-19-2175. Epub 2020 Feb 10.
5
Population dynamics of normal human blood inferred from somatic mutations.从体细胞突变推断正常人体血液的种群动态。
Nature. 2018 Sep;561(7724):473-478. doi: 10.1038/s41586-018-0497-0. Epub 2018 Sep 5.
6
Hierarchical tissue organization as a general mechanism to limit the accumulation of somatic mutations.层次组织的组织学作为一种普遍的机制,限制了体细胞突变的积累。
Nat Commun. 2017 Feb 23;8:14545. doi: 10.1038/ncomms14545.
7
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.慢性髓性白血病的定量建模:来自放射生物学的见解。
Blood. 2012 May 10;119(19):4363-71. doi: 10.1182/blood-2011-09-381855. Epub 2012 Feb 21.
8
Clonal evolution in cancer.癌症中的克隆进化。
Nature. 2012 Jan 18;481(7381):306-13. doi: 10.1038/nature10762.
9
Dynamics of mutant cells in hierarchical organized tissues.层次组织组织中突变细胞的动力学。
PLoS Comput Biol. 2011 Dec;7(12):e1002290. doi: 10.1371/journal.pcbi.1002290. Epub 2011 Dec 1.
10
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.BCR-ABL 激酶结构域突变赋予的耐药性决定了慢性髓性白血病患者预先存在耐药的风险。
PLoS One. 2011;6(11):e27682. doi: 10.1371/journal.pone.0027682. Epub 2011 Nov 28.